Compare Abeona Therapeutics Inc (ABEO) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Endeavour Silver Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Endeavour Silver Corp trades at $7.57 (market cap $2.37B). The key difference: Endeavour Silver Corp is far larger — about 6.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | EXK | |
|---|---|---|
Market Cap | $373.32M | $2.37B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $14.12 |
52-Week Low | $4.17 | $4.84 |
Enterprise Value | $228.22M | $2.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Endeavour Silver (EXK) trades at $8.51, down 0.58% on the day, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 results with earnings of $0.21 per share beating expectations, driven by record production. However, full-year 2025 showed a net loss of $119.10 million despite revenue growth. Recent news highlights high-grade mineralization discoveries at its Terronera mine, supporting future production potential.
The outlook is mixed: analyst consensus is strongly bullish (78.57% buy ratings), but profitability remains a concern with negative margins. Key risks include execution on growth projects and silver price volatility. Upside catalysts hinge on sustained operational improvements and favorable commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
